TheraRadar
← Back
Data updated: Jun 28, 2026

CASPER PHARMA LLC

Big Pharma

CASPER PHARMA LLC is a major pharmaceutical company focused on Cardiovascular, Infectious Disease, Gastroenterology. Key products include TIOCYSTIN.

1949
Since
17
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
8 Small Molecules

CASPER PHARMA LLC's Key Drugs

CASPER PHARMA LLC's core commercial portfolio centers on TIOCYSTIN, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.

CASPER PHARMA LLC's Recent FDA Approvals

CASPER PHARMA LLC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

CASPER PHARMA LLC's Therapeutic Areas

CASPER PHARMA LLC's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 8 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 33%
3 drugs
Infectious Disease 22%
2 drugs
Gastroenterology 22%
2 drugs
Oncology 11%
1 drugs
Immunology 11%
1 drugs

CASPER PHARMA LLC's Top Competitors

CASPER PHARMA LLC's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Sanofi, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

CASPER PHARMA LLC Pipeline Snapshot

Active clinical trials for CASPER PHARMA LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • TIOCYSTIN leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling